Brief: Jw (Cayman) Therapeutics Says Ind Approval From China's Nmpa For Clinical Trial Of Carteyva In Pediatric & Young Adult Patients
20/04/2022 12:07
April 20 (Reuters) - JW (Cayman) Therapeutics Co Ltd
2126.HK :
* IND APPROVAL FROM CHINA'S NMPA FOR CLINICAL TRIAL OF
CARTEYVA IN
PEDIATRIC & YOUNG ADULT PATIENTS
Source text for Eikon: ID:nHKS38P5KD
Further company coverage: 2126.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on JW (Cayman) Therapeutics Co
See all newsChina pharma industry not impacted by Beijing scrutiny of sensitive tech deals, JW chief says
Brief: JW (Cayman) Therapeutics Appoints Tian Feng As CEO, Executive Director
Australia's Imugene gains on alliance with JW Therapeutics for tumour treatment
Brief: JW (Cayman) Therapeutics H1 Net Income RMB -267.3 Million
Brief: JW (Cayman) Therapeutics Grants Juno Therapeutics Non-Exclusive License